Ultrasound-guided dexmedetomidine combination with modified high fascia iliaca compartment block for arthroscopic knee surgery: what is the optimal dose of dexmedetomidine?
Modified high fascia iliaca compartment block
Postoperative chronic pain
Total knee arthroplasty
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
06 Dec 2023
06 Dec 2023
Historique:
received:
26
07
2023
accepted:
27
11
2023
medline:
11
12
2023
pubmed:
7
12
2023
entrez:
6
12
2023
Statut:
epublish
Résumé
Total knee arthroplasty (TKA) is a common orthopedic procedure for end-stage knee osteoarthritis. Although effective in relieving pain and improving function, postoperative pain is still a common and distressing problem for many patients. This study aims to investigate efficacy of combined administration of dexmedetomidine and modified high fascia iliaca compartment block (H-FICB) in managing acute and chronic pain after TKA, as well as to identify the optimal dosage of dexmedetomidine. A double-blind, randomized controlled trial was conducted to evaluate the effects of dexmedetomidine in patients undergoing TKA. A total of 96 patients undergoing TKA were randomly assigned to one of three groups, were treated with different doses of dexmedetomidine All groups received H-FIB. Pain scores, opioid consumption, side effects, and quality of life were recorded 48 h postoperatively. The intraoperative consumption of remifentanil and propofol in Group D In comparison to the other two groups, the administration of combined dexmedetomidine and H-FIB resulted in a significant reduction in pain scores, opioid consumption, and side effects. The optimal dosage of dexmedetomidine was determined to be 1 μg/kg, which provided the most favorable pain relief with minimal adverse effects.
Sections du résumé
BACKGROUND
BACKGROUND
Total knee arthroplasty (TKA) is a common orthopedic procedure for end-stage knee osteoarthritis. Although effective in relieving pain and improving function, postoperative pain is still a common and distressing problem for many patients. This study aims to investigate efficacy of combined administration of dexmedetomidine and modified high fascia iliaca compartment block (H-FICB) in managing acute and chronic pain after TKA, as well as to identify the optimal dosage of dexmedetomidine.
METHODS
METHODS
A double-blind, randomized controlled trial was conducted to evaluate the effects of dexmedetomidine in patients undergoing TKA. A total of 96 patients undergoing TKA were randomly assigned to one of three groups, were treated with different doses of dexmedetomidine All groups received H-FIB. Pain scores, opioid consumption, side effects, and quality of life were recorded 48 h postoperatively.
RESULTS
RESULTS
The intraoperative consumption of remifentanil and propofol in Group D
DISCUSSION
CONCLUSIONS
In comparison to the other two groups, the administration of combined dexmedetomidine and H-FIB resulted in a significant reduction in pain scores, opioid consumption, and side effects. The optimal dosage of dexmedetomidine was determined to be 1 μg/kg, which provided the most favorable pain relief with minimal adverse effects.
Identifiants
pubmed: 38057762
doi: 10.1186/s12871-023-02361-0
pii: 10.1186/s12871-023-02361-0
pmc: PMC10699007
doi:
Substances chimiques
Dexmedetomidine
67VB76HONO
Analgesics, Opioid
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
400Subventions
Organisme : Social Development Foundation of Nantong City
ID : MS12020026
Organisme : Social Development Foundation of Nantong City
ID : MS12020026
Organisme : Social Development Foundation of Nantong City
ID : MS12020026
Organisme : Social Development Foundation of Nantong City
ID : MS12020026
Organisme : Social Development Foundation of Nantong City
ID : MS12020026
Informations de copyright
© 2023. The Author(s).
Références
BMJ Open. 2012 Feb 22;2(1):e000435
pubmed: 22357571
Acta Orthop Traumatol Turc. 2021 Mar;55(2):134-140
pubmed: 33847575
BMC Geriatr. 2021 Dec 1;21(1):669
pubmed: 34852764
Mediators Inflamm. 2020 Apr 3;2020:2120971
pubmed: 32317860
J Orthop Surg Res. 2017 Feb 2;12(1):22
pubmed: 28153031
Anesth Analg. 1998 Jul;87(1):93-7
pubmed: 9661553
J Arthroplasty. 2021 Jan;36(1):122-129.e1
pubmed: 32694032
Reg Anesth Pain Med. 2019 Feb 22;:
pubmed: 30798268
Curr Protein Pept Sci. 2013 Feb;14(1):21-32
pubmed: 23441898
Can J Anaesth. 2016 May;63(5):569-76
pubmed: 26830642
Auton Neurosci. 2014 Jul;183:111-5
pubmed: 24656574
Minerva Anestesiol. 2018 Oct;84(10):1134-1141
pubmed: 29338141
Minerva Anestesiol. 2017 Jun;83(6):590-597
pubmed: 28106354
Clin Ther. 2017 Jan;39(1):89-97.e1
pubmed: 27955918
Int J Mol Sci. 2017 Nov 21;18(11):
pubmed: 29160850
Medicine (Baltimore). 2017 Jul;96(27):e7382
pubmed: 28682889
Pain Physician. 2017 Nov;20(7):671-680
pubmed: 29149146
Knee Surg Sports Traumatol Arthrosc. 2021 Dec;29(12):4022-4031
pubmed: 32975624
Lancet Neurol. 2014 Sep;13(9):924-35
pubmed: 25142459
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001791
pubmed: 20091522
Drugs. 2000 Feb;59(2):263-8; discussion 269-70
pubmed: 10730549
Sci Rep. 2018 Mar 21;8(1):4935
pubmed: 29563509
Br J Anaesth. 2013 Jun;110(6):915-25
pubmed: 23587874
Mediators Inflamm. 2020 May 9;2020:6136105
pubmed: 32454792
Pain Physician. 2019 Sep;22(5):479-488
pubmed: 31561647
Pain Ther. 2022 Jun;11(2):529-543
pubmed: 35167059
Arthritis Care Res (Hoboken). 2013 Nov;65(11):1795-1803
pubmed: 23740860
Pain Ther. 2021 Dec;10(2):1649-1662
pubmed: 34595723
Cochrane Database Syst Rev. 2013 Jul 24;(7):CD008307
pubmed: 23881791
Can J Anaesth. 2004 Apr;51(4):358-63
pubmed: 15064265
Medicine (Baltimore). 2021 Apr 9;100(14):e25450
pubmed: 33832151
Front Neurosci. 2020 May 05;14:330
pubmed: 32431587
Pain. 2001 May;92(1-2):147-57
pubmed: 11323136
J Musculoskelet Neuronal Interact. 2021 Mar 1;21(1):104-112
pubmed: 33657760